Subscribe

Thyrocare Technologies Limited (THYROCARE.NS)

INR530.25 -10.20 (-1.89%)
IN NSE Healthcare Medical - Diagnostics & Research
Address D/37-3, TTC Industrial Area 400703
Navi Mumbai, IN
CEO Rahul Franklin Guha
Website thyrocare.com
IPO 2016-05-10
ISIN INE594H01019

Explore sections of this company profile

Also trades on Bombay Stock Exchange · THYROCARE.BO (INR) National Stock Exchange of India · THYROCARE.NS (INR)
Description

Thyrocare Technologies Limited, an Indian enterprise, delivers a comprehensive array of diagnostic testing solutions to individual patients, medical laboratories, and healthcare providers throughout the nation. Its operations are structured across three main segments: Diagnostic Testing Services, Imaging Services, and other miscellaneous endeavors. The company's primary focus involves conducting numerous medical diagnostic analyses and specialized test panels aimed at the timely detection and effective management of various health conditions. These include, among others, disorders related to the thyroid, growth, metabolism, autoimmune responses, diabetes, anemia, cardiovascular health, infertility, COVID-19, and a broad spectrum of infectious diseases. Under its "Aarogyam" brand, Thyrocare offers 34 distinct profiles of tests, providing patients with extensive wellness and preventative health check-ups. Furthermore, the company sells "Sugarscan" branded glucometers and glucostrips, along with various consumable products and radiopharmaceuticals. Founded in 1996, Thyrocare Technologies Limited is headquartered in Navi Mumbai, India, and functions as a subsidiary of Docon Technologies Private Limited.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
INR530.25 -10.20 (-1.89%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
545.9K
Beta
0.47
Float Shares
15.30M
Free Float %
28.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+3.33% +5.66% +23.01% +22.12% +5.22% +10.12% +54.40% +215.99% +42.67% +133.90% +137.94%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
530.25
DCF (Unlevered) 705.10 +33.0%
DCF (Levered) 778.52 +46.8%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 3 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
11.96
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Diagnostics & Research: +7.9%
    +20.6% ★ Q1'26: +19.7% (vs Q1'25)
  • ✗
    EPS growth Medical - Diagnostics & Research: +30.8%
    -40.6% Q1'26: -28.4% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%
    +21.7% ★ Q1'26: +49.7% (vs Q1'25)
  • ✓
    EBIT margin Medical - Diagnostics & Research: +9.6%
    +24.5% ★ Q1'26: +27.3% (vs Q1'25)
  • ✓
    ROIC Medical - Diagnostics & Research: +5.2%
    +37.3% ★ Q1'26: +44.3% (vs Q1'25)
  • ✗
    Share dilution Medical - Diagnostics & Research: 0.0%
    +197.2% Q1'26: +203.1% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×
    0.19× ★ Q1'26: 0.17× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.35) × ERP
WACC = 99% × Ke + 1% × Kd (5.5%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 705.11 Current price: 530.25
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2016
actual 		Mar 2017
actual 		Mar 2018
actual 		Mar 2019
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2022
actual 		Mar 2023
actual 		Mar 2024
actual 		Mar 2025
actual 		Mar 2026
2 Rev. Ana.
3 EPS Ana. 		Mar 2027
2 Rev. Ana.
3 EPS Ana. 		Mar 2028
2 Rev. Ana.
3 EPS Ana.
Revenue
2.41B
est: 1.83B (+31.7%)
3.07B
est: 3.07B (+0.0%)
3.56B
est: 3.61B (-1.3%)
4.03B
est: 4.05B (-0.5%)
4.33B
est: 4.38B (-1.0%)
4.95B
est: 4.95B (-0.1%)
5.89B
est: 5.96B (-1.2%)
5.27B
est: 5.31B (-0.8%)
5.72B
est: 5.65B (+1.2%)
6.87B
est: 6.85B (+0.3%)
8.17B
8.14B – 8.21B
+19.3% YoY
9.50B
9.46B – 9.54B
+16.3% YoY
11.00B
10.95B – 11.05B
+15.8% YoY
EBITDA
940.49M
est: 594.39M (+58.2%)
999.20M
est: 996.51M (+0.3%)
1.65B
est: 1.30B (+27.3%)
1.65B
est: 1.94B (-15.2%)
1.74B
est: 1.84B (-5.4%)
1.84B
est: 1.70B (+7.9%)
2.64B
est: 1.99B (+32.6%)
1.31B
est: 2.18B (-39.8%)
1.48B
est: 2.47B (-40.1%)
2.04B
est: 2.97B (-31.4%)
2.56B
2.55B – 2.57B
-13.7% YoY
2.98B
2.97B – 2.99B
+16.3% YoY
3.45B
3.43B – 3.47B
+15.8% YoY
EBIT
758.12M
est: 464.52M (+63.2%)
819.42M
est: 778.78M (+5.2%)
1.45B
est: 856.74M (+69.7%)
1.39B
est: 1.49B (-6.6%)
1.42B
est: 1.39B (+2.2%)
1.53B
est: 1.33B (+14.9%)
2.30B
est: 1.56B (+47.3%)
922.40M
est: 1.70B (-45.9%)
1.01B
est: 1.94B (-47.9%)
1.48B
est: 1.65B (-10.0%)
1.97B
1.96B – 1.98B
+19.3% YoY
2.29B
2.28B – 2.30B
+16.3% YoY
2.65B
2.64B – 2.66B
+15.8% YoY
Net Income
518.00M
709.65M
est: 234.35M (+202.8%)
932.75M
est: 525.25M (+77.6%)
851.40M
est: 1.06B (-19.5%)
884.00M
est: 925.50M (-4.5%)
1.13B
est: 880.25M (+28.5%)
1.76B
est: 1.03B (+71.0%)
644.90M
est: 1.12B (-42.7%)
707.60M
est: 1.28B (-44.7%)
915.10M
est: 950.01M (-3.7%)
1.59B
1.55B – 1.61B
+67.6% YoY
1.82B
1.72B – 1.88B
+14.0% YoY
2.26B
2.17B – 2.31B
+24.6% YoY
SGA
106.14M
est: 165.61M (-35.9%)
225.57M
est: 277.65M (-18.8%)
314.05M
est: 1.30B (-75.8%)
406.60M
est: 1.30B (-68.7%)
388.60M
est: 1.48B (-73.7%)
372.40M
est: 1.38B (-73.0%)
395.00M
est: 1.61B (-75.5%)
435.30M
est: 1.76B (-75.3%)
656.70M
est: 2.01B (-67.3%)
774.20M
est: 862.87M (-10.3%)
1.03B
1.03B – 1.03B
+19.3% YoY
1.20B
1.19B – 1.20B
+16.3% YoY
1.39B
1.38B – 1.39B
+15.8% YoY
EPS
10.06
8.00
est: 4.37 (+82.9%)
17.36
est: 6.01 (+188.6%)
15.95
est: 5.36 (+197.6%)
16.74
est: 6.91 (+142.4%)
21.41
est: 7.12 (+200.7%)
33.30
est: 11.10 (+200.1%)
12.16
est: 4.40 (+176.6%)
13.42
est: 4.93 (+172.0%)
17.28
est: 5.97 (+189.6%)
10.00
9.74 – 10.13
+67.6% YoY
11.40
10.83 – 11.78
+14.0% YoY
14.20
13.66 – 14.52
+24.6% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-08 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-07 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-04 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-22 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-16 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
411.69M
OE per share TTM
7.71
Owner's Yield
0.54%
Maintenance CapEx ratio
29.71%
Maint CapEx / Avg PPE
32.1%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
1.20M
Shares Outstanding
53.05M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Rahul Franklin Guha MD, Chief Executive Officer & Chairman 56M male
Brijesh Kumar Company Secretary & Compliance Officer — male
Kapil Gupta Strategy Manager — male
Pratik Hire Head of Strategy & Investor Relations — male
Preet Joshi Strategy Manager — male
Preet Kaur Vice President of Lab Operations & Quality — female
Rajdeep Panwar Chief Commercial Officer — male
Ramesh Kinha Chief Operating Officer — —
Aditya Shinde Vice President — male
Vikram Gupta Chief Financial Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Diagnostics & Research